The SCN2A Gene Dravet Syndrome Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the SCN2A gene, which have been linked to Dravet Syndrome. Dravet Syndrome is a severe form of epilepsy that emerges in the first year of life, characterized by frequent, prolonged seizures often triggered by high temperatures or fever. Beyond seizures, individuals with Dravet Syndrome may also experience developmental delays, speech and walking issues, sleep disturbances, and other health complications.
The SCN2A gene plays a crucial role in the function of brain cells by coding for a protein that is essential for the proper transmission of electrical signals in the nervous system. Mutations in this gene can disrupt these signals, leading to the symptoms observed in Dravet Syndrome. Identifying mutations in the SCN2A gene can confirm a diagnosis of Dravet Syndrome, allowing for tailored treatment plans that can significantly improve the quality of life for affected individuals.
The test offered by DNA Labs UAE involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in their state-of-the-art facilities. The cost of the test is 4400 AED, which reflects the sophisticated technology and expertise required to accurately identify mutations in the SCN2A gene.
By opting for the SCN2A Gene Dravet Syndrome Genetic Test, families and individuals gain access to crucial information that can guide clinical decisions, from medication choices to lifestyle adjustments, ultimately leading to better management of Dravet Syndrome.
The SCN9A Gene Dravet Syndrome Modifier Genetic Test is a specialized diagnostic assessment conducted at DNA Labs UAE, designed to identify mutations in the SCN9A gene, which are known to modify the severity and characteristics of Dravet Syndrome. Dravet Syndrome is a severe form of epilepsy that begins in infancy and is often associated with gene mutations, including those in the SCN1A gene. However, recent research has identified that variations in the SCN9A gene can also influence the disease's course and response to treatment.
This test, priced at 4400 AED, is crucial for individuals diagnosed with Dravet Syndrome or families with a history of the condition, as it provides valuable insights into the genetic underpinnings of the disease. Understanding the specific genetic variations can guide personalized treatment strategies, potentially improving the quality of life for those affected. The testing process at DNA Labs UAE involves a comprehensive analysis of the SCN9A gene, employing state-of-the-art genetic sequencing technologies to ensure accurate and reliable results.
By opting for the SCN9A Gene Dravet Syndrome Modifier Genetic Test, patients and healthcare providers can gain a deeper understanding of the genetic factors contributing to Dravet Syndrome, paving the way for more targeted and effective interventions.
The FRRS1L gene dysautonomia, associated with mutations in the FRRS1L gene, is a rare genetic disorder affecting the autonomic nervous system, which controls involuntary bodily functions such as heart rate, digestion, and respiratory rate. This condition can lead to a wide range of symptoms, including sensory neuropathy, autonomic dysfunction, and, in some cases, intellectual disability or developmental delays.
To diagnose this condition, a specific genetic test targeting the FRRS1L gene can be conducted. This test is crucial for confirming the diagnosis, understanding the condition's progression, and assisting in the management and treatment planning for affected individuals. In the UAE, DNA Labs UAE offers this specialized genetic testing service.
The cost of the FRRS1L-related genetic test at DNA Labs UAE is 4400 AED. The test involves analyzing the patient's DNA sample, usually obtained through a blood draw, to identify mutations in the FRRS1L gene that are indicative of the disorder. Given the complexity and the specialized nature of this genetic test, it represents a critical step towards personalized medicine for patients with symptoms suggestive of FRRS1L gene dysautonomia, offering them a clearer path to appropriate interventions and support.
The SCN2A Gene Convulsions Benign Familial Infantile 3 Genetic Test is a specialized diagnostic procedure designed to identify mutations in the SCN2A gene, which are linked to Benign Familial Infantile Epilepsy (BFIE) type 3. This condition is characterized by the onset of seizures or convulsions in infants, typically between the ages of 3 months and 12 months. These seizures are generally not associated with long-term neurological deficits, making the condition "benign" in nature. However, early and accurate diagnosis is crucial for the effective management and treatment of the seizures, which can significantly improve the quality of life for affected infants.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, this test offers a comprehensive analysis of the SCN2A gene to detect any mutations that could be responsible for the disorder. The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed using advanced genetic sequencing technologies.
The cost of the SCN2A Gene Convulsions Benign Familial Infantile 3 Genetic Test is 4400 AED. This price reflects the intricate processes and sophisticated technology involved in accurately identifying the genetic variations linked to this specific form of epilepsy. By opting for this test, parents and healthcare providers can gain valuable insights into the genetic underpinnings of the infant's condition, enabling tailored treatment plans and informed decisions about care and management.
The PRRT2 gene convulsions familial infantile with paroxysmal choreoathetosis genetic test is a specialized diagnostic tool used to identify mutations in the PRRT2 gene, which are linked to a rare neurological disorder. This condition is characterized by early-onset convulsions, typically seen in infants, and can evolve into paroxysmal choreoathetosis in later life, manifesting as sudden, involuntary movements. The test plays a crucial role in confirming the diagnosis, enabling early intervention and tailored management strategies for affected individuals.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient's DNA to detect abnormalities in the PRRT2 gene that are indicative of the disorder. The cost of the test is set at 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic variations associated with this condition. By opting for this test, families can gain valuable insights into the genetic underpinnings of the disorder, facilitating informed decisions about care and treatment options.
The "IGBP1 Gene Corpus Callosum Agenesis with Mental Retardation, Ocular Coloboma, and Micrognathia Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE. This test is designed to detect mutations in the IGBP1 gene, which have been associated with a rare congenital condition characterized by the absence or underdevelopment of the corpus callosum (the part of the brain that connects the two hemispheres), intellectual disabilities, ocular coloboma (a defect in the eye's iris or retina), and micrognathia (a condition where the jaw is significantly smaller than normal).
The test plays a crucial role in the early diagnosis and management of the condition, providing essential information for healthcare providers and families. By understanding the genetic underpinnings of these symptoms, medical professionals can offer more personalized care plans, anticipate potential complications, and provide genetic counseling to affected families.
The cost of the test is 4400 AED, reflecting the advanced technology and expertise required to accurately identify mutations in the IGBP1 gene. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, patients and healthcare providers can expect reliable and comprehensive results that can significantly impact the management of this rare condition.
The "TUBB3 Gene Cortical Dysplasia Complex with Other Brain Malformations Type 1 Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the TUBB3 gene, which are associated with a range of developmental brain abnormalities. This condition, known as Tubulinopathy, encompasses a spectrum of disorders that can lead to cortical dysplasia, a malformation of the brain cortex, among other neurological manifestations. These malformations can significantly impact brain function, leading to developmental delays, movement disorders, and epilepsy.
The test involves analyzing the patient's DNA to look for specific genetic alterations in the TUBB3 gene that are known to cause these complex brain malformations. Early diagnosis through genetic testing can be crucial for the management of the condition, allowing for tailored treatment plans and interventions that can improve the quality of life for affected individuals.
Performed at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the test cost is set at 4400 AED. This investment covers the detailed analysis required to detect the presence of mutations in the TUBB3 gene, providing essential information for patients and their families. Through this test, DNA Labs UAE aims to offer hope and support to those facing the challenges associated with cortical dysplasia complex and other related brain malformations.
The TUBB2A Gene Cortical Dysplasia Complex with Other Brain Malformations Type 5 Genetic Test is a specialized diagnostic examination offered at DNA Labs UAE. This test specifically targets the TUBB2A gene, mutations of which are associated with cortical dysplasia complex type 5, a rare genetic disorder that affects brain development. This condition can lead to a range of neurological problems, including developmental delays, seizures, and abnormalities in brain structure.
The test is designed to identify mutations in the TUBB2A gene, providing crucial information that can assist in the diagnosis, management, and treatment planning for affected individuals. By employing advanced genetic sequencing technologies, DNA Labs UAE ensures a high level of accuracy and reliability in the test results.
The cost of the TUBB2A Gene Cortical Dysplasia Complex with Other Brain Malformations Type 5 Genetic Test is 4400 AED. This price reflects the sophisticated nature of the genetic analysis and the specialized expertise required to interpret the results. For families facing the challenges of cortical dysplasia and related brain malformations, this test represents a valuable tool in understanding the genetic underpinnings of the condition and navigating the path forward in terms of medical care and support.
The "CNTNAP2 Gene Cortical Dysplasia-Focal Epilepsy Syndrome Genetic Test" is a specialized diagnostic examination conducted to detect mutations in the CNTNAP2 gene, which are linked to the development of Cortical Dysplasia-Focal Epilepsy (CDFE) syndrome. This condition is characterized by abnormalities in the brain's cortex that lead to epilepsy and other neurological issues. The test is a crucial tool for clinicians in diagnosing CDFE syndrome, enabling them to provide targeted treatments and management plans for affected individuals.
This genetic test is available at DNA Labs UAE, a leading facility known for its advanced diagnostic services and state-of-the-art technology. The cost of the test is 4400 AED, reflecting the sophisticated nature of the genetic analysis and the detailed insights it provides into the patient's condition. By identifying specific mutations in the CNTNAP2 gene, this test plays a vital role in the early detection and intervention of Cortical Dysplasia-Focal Epilepsy Syndrome, offering hope and improved outcomes for patients and their families.
The CFL1 gene plays a crucial role in various cellular processes, including cell division and movement. Mutations in this gene have been linked to corticobasal degeneration (CBD), a rare, progressive neurodegenerative disorder that affects the brain's cortex and basal ganglia, leading to a range of symptoms such as difficulty in movement, cognitive impairments, and behavioral changes. To aid in the diagnosis and understanding of the genetic basis of CBD associated with the CFL1 gene, DNA Labs UAE offers a specialized genetic test. Priced at 4400 AED, this test analyzes the CFL1 gene for specific mutations that may contribute to the development of corticobasal degeneration. By identifying these mutations, healthcare providers can gain valuable insights into the condition, enabling them to make more informed decisions regarding the patient's care and management.
